Downstream formulation of the inactivated combined ovine black disease and braxy antigen begins as aseptic dilution into an aqueous injectable suspension. The API is a whole-culture bacterin-toxoid, not a purified small molecule. Aseptic processing rather than terminal filtration therefore governs all subsequent operations. The antigen concentrate is held at 5±3 °C in jacketed stainless steel vessels before addition to a sterile phosphate-buffered diluent. The diluent contains 0.01–0.02% w/v thiomersal in multi-dose presentations and is adjusted to pH 6.8–7.4 with 0.1 M hydrochloric acid or sodium hydroxide. Osmolality is corrected to 280–320 mOsm/kg by freezing point depression. Aluminium hydroxide adjuvant is incorporated at 1.5–3.0 mg Al³⁺ per mL under low-shear mixing at 150–300 rpm. Mixing is sustained for 30–60 min to stabilise antigen-adjuvant association. Terminal filtration is not applied after adjuvant addition because both the bacterin particles and aluminium gel exceed 0.22 µm pore diameter. All components upstream are sterilised by moist heat at 121 °C for 15 min where thermostable, or by 0.22 µm sterilising-grade filtration where thermolabile. Filling occurs on peristaltic or rotary piston lines within ISO 14644-1 Class ISO 7 cleanrooms with unidirectional airflow of 0.36–0.54 m/s. In-process checks include pH stability after 2 h at 25 °C, osmolality, and sedimentation ratio under gravitational stress. Final dose volume for sheep is typically 1–2 mL subcutaneous. Potency testing for analogous clostridial bacterin-toxoids follows 9 CFR 113.110 and 9 CFR 113.107. Batch-to-batch variance on production lines is most often traced to adjuvant lot particle size shifts above 12 µm, which alter settling and reduce syringeability.

What Physical Stresses Limit Lyophilised Powder Viability for the Inactivated Ovine Antigen?

Lyophilisation is used to convert the liquid API into a powder for reconstitution injection, not for oral solid dosage manufacture. The critical process window is narrow and failure at production scale is usually caused by collapse or meltback rather than low antigen recovery. Freezing is controlled at 0.5–1.0 °C/min to −45 °C to avoid ice-crystal damage to the bacterial cell wall fragments and toxoid aggregates. Primary drying is executed at shelf temperatures between −20 °C and −15 °C with chamber pressure at 80–200 µbar for 36–72 h. Secondary drying is ramped stepwise to 20–30 °C until residual moisture reaches 1.5–3.0% w/w. Lyoprotectant systems based on trehalose dihydrate 4.0–6.0% w/v, mannitol 2.0–4.0% w/v, and dextran 40 1.0–2.0% w/v are introduced before freezing. Pilot-scale lyophilisers with shelf areas of 0.5–2 m², condenser setpoints at −65 °C, and capacitance manometer-controlled vacuum provide consistent ejector pressure. Batch failures observed on manufacturing lines include meltback when ice nucleation is non-uniform and collapsed cake with residual moisture above 5% w/w. The reconstituted powder must produce a suspension free of visible aggregates larger than 150 µm. Published data for this specific combined ovine black disease and braxy antigen in lyophilised form is limited; process transfer therefore requires vial heat transfer coefficient mapping and conservative ramp rates.

Multivalent Clostridial Blending and Antigen Interference Thresholds

The combined API is rarely formulated as a monovalent product in commercial ovine vaccination programmes. It is introduced into stainless steel blending vessels of 200–1000 L together with toxoids or bacterins for Clostridium perfringens types A, B, C and D, Clostridium tetani, and, in some regional products, Clostridium chauvoei. The addition sequence is not arbitrary. Soluble toxoids are diluted before particulate bacterins are added, and aluminium hydroxide adsorption is performed last. Antigenic mass per dose is normally tracked by sandwich ELISA calibrated against reference sera; potency is confirmed by toxin neutralisation in laboratory animals. Antigenic competition can reduce serological responses by 10–30% when four or more clostridial antigens are co-formulated at high antigen loads, as reported in published ovine vaccination trial reviews. Published data for this specific combined API in multivalent regimens is limited. Equipment requirements include bottom-entry agitators operating at 100–250 rpm, load cells with 0.5 kg resolution for gravimetric component addition, and clean-in-place systems validated for 80–85 °C alkaline wash. The final blend is held at 5±3 °C until filling. Any hold time beyond 72 h must be supported by antigen concentration stability data. This is because aluminium hydroxide re-equilibration can alter ligand exchange and affect potency. Release testing for multivalent clostridial vaccines follows the general provisions of Ph. Eur. 0062 and relevant USDA 9 CFR parts.

Oil-adjuvanted depot preparations are evaluated when prolonged antigen release is required in extensive grazing systems. The aqueous antigen phase is emulsified into light mineral oil containing mannide monooleate at an oil phase ratio of 45–55% v/v. A high-shear rotor-stator mixer operating at 6000–10,000 rpm for 5–10 min produces a water-in-oil emulsion with a median droplet size d50 of 2–10 µm. Droplet size is measured by laser diffraction immediately after emulsification and again after 24 h at 25 °C to detect coalescence. Viscosity is maintained between 50–150 mPa·s at 25 °C to remain syringeable through 18–21 G needles. In injection force testing with a texture analyser at 1 mm/s, the maximum force is typically held below 25 N. Temperature during emulsification must not exceed 35 °C to avoid antigen denaturation at the oil-water interface. Sterility is assured by pre-sterilising the oil phase by dry heat at 160 °C for 2 h and the aqueous phase by filtration; the final emulsion cannot be sterile-filtered. Batch-to-batch variation in droplet size is most often related to rotor-stator gap wear beyond 0.1 mm or viscosity drift in the adjuvant. Published data for this specific combined ovine black disease and braxy antigen in water-in-mineral-oil emulsion is limited; experimental stability studies must include emulsion breaking ratio and free aqueous phase determination.

When Regional Autogenous Vaccine Manufacturing Is Permitted under Ovine Flock Health Plans

Veterinary regulations in several jurisdictions allow licensed veterinary biological establishments to prepare autogenous clostridial vaccines from isolates obtained from a specific flock or region. The inactivated combined API may serve as the production baseline or as the platform for a custom isolate addition. Isolate identity is confirmed by MALDI-TOF mass spectrometry or 16S rRNA sequencing before fermentation. Toxigenic capacity is assessed by polymerase chain reaction for the alpha toxin gene of Clostridium septicum and the alpha toxin gene of Clostridium novyi type B. Inactivation is revalidated for each fermentation batch with formaldehyde at 0.4–0.6% v/v at 37±1 °C for 14–28 days. Detoxification is confirmed by absence of growth in thioglycollate medium and by mouse toxicity testing, not by visual inspection. The final product is released under the specific autogenous permit rather than a full marketing authorisation. Published data for this specific API in autogenous applications is limited, so matrix validation must include deliberate toxin-spiking studies to show that the inactivation process can clear challenge-level toxigenic activity. Equipment trains are smaller: stainless steel bioreactors of 50–200 L, in-line pH control at 7.0–7.4, and static inactivation tanks with slow agitation at 50–100 rpm. Cold-chain transport at 2–8 °C is mandatory because autogenous product is often used within 30 days.

Tablet and Capsule Dosage Forms Are Not Licensed for This Biological API

The terms tablet, capsule, granule, and premix appear in the API description, but they do not represent viable downstream routes for an inactivated whole-culture clostridial bacterin-toxoid. Compression forces above 50 MPa on rotary tablet presses generate local shear, interparticulate friction, and adiabatic heating sufficient to denature toxoid epitopes. Magnesium stearate at 0.5–1.5% w/w, a standard tableting lubricant, is hydrophobic and impedes reconstitution of the lyophilised antigen. Gastric pH of 1.5–3.5 and intestinal proteases destroy the antigen before systemic immune recognition. Feed pelleting temperatures above 70 °C and long residence times in premix carriers degrade the antigen mass. No pharmacopoeial monograph or regulatory pathway supports oral solid dosage forms for inactivated clostridial vaccines in sheep. Accordingly, tableting and encapsulation are excluded from the application scope; the correct powder form is a lyophilised injection cake, not a granulation for oral administration.

Final aqueous solutions for injection are prepared by diluting the liquid API or reconstituting the lyophilised powder with sterile water for injection. The target solution must remain homogeneous through 2–8 °C cold-chain storage, with no visible precipitation after 72 h at 5±3 °C. In large-flock automatic syringe systems, the final solution viscosity is held below 10 mPa·s and particle aggregates are excluded above 20 µm to prevent nozzle blockage. Needle-free injectors, where used, impose tighter particle size limits and require wave-force pressure validation above 180 bar to generate a robust jet. The solution is filled into Type I glass vials or multilayer polypropylene bags under aseptic conditions. Container closure integrity is verified by dye ingress testing according to ASTM F1929 or equivalent. A filtered air supply and condensate collection in automatic filling lines reduce the risk of microbial ingress. Published data for this specific combined vaccine in needle-free ovine vaccination is limited; each device must be tested with the final formulation to confirm no antigen loss in the pressure chamber.